Novel Drugs for Treating Gynecologic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 5 January 2025 | Viewed by 1906
Special Issue Editors
Interests: ovarian cancer; chemotherapy; cellular diagnostics
Interests: gynecological cancer; ovarian cancer; endometrial cancer; cervical cancer; molecular biology; molecular genetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is titled “Novel Drugs for Treating Gynecologic Cancers”.
Gynecologic cancer treatment has reached a major turning point thanks to the development of molecularly targeted agents and immune-checkpoint inhibitors.
In particular, in ovarian cancer treatment, testing for BRCA and HRD status is expected to further improve prognosis by combining molecular targeted agents with different mechanisms of action.
This Special Issue aims to collect original research studies and review articles (either systematic or discursive), clinical trials, and short communications adding to the current knowledge and showing potential future approaches of novel agents for gynecologic cancers.
Prof. Dr. Tadahiro Shoji
Prof. Dr. Hiroaki Itamochi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecological cancers
- novel treatment strategies
- cytotoxic chemotherapeutic agents
- molecularly targeted agents
- immune-checkpoint inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
